Literature DB >> 30132643

Severity of hereditary angioedema, prevalence, and diagnostic considerations.

Jonathan A Bernstein1.   

Abstract

Hereditary angioedema (HAE) is a rare disorder, characterized by intermittent attacks of swelling in any part of the body, without the presence of hives. This lifelong disease typically presents in the first 2 decades of life, and is commonly associated with a deficiency in functional C1 esterase inhibitor (C1-INH) activity. C1-INH levels may be decreased or normal, with an accompanied decrease in functionality, depending on the type of HAE present. The frequency and severity of attacks are highly variable among patients with HAE, but can have a significant impact on a patient's quality of life, and may be fatal if not properly managed. Early diagnosis of the disease can lead to the development of an individualized treatment plan to assist with prevention and management of angiodema attacks. Delays in diagnosis remain, as healthcare professionals often fail to include HAE in the differential diagnosis when patients present with attacks, and patients therefore often go undiagnosed or are misdiagnosed for several years before a diagnosis of HAE is made. It is important for providers to recognize the most common clinical features of HAE and how to evaluate patients to effectively diagnose, prevent, and treat future attacks.

Entities:  

Mesh:

Year:  2018        PMID: 30132643

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  10 in total

1.  Hereditary Angioedema Presenting as Isolated Jejunal Swelling.

Authors:  Rizwan Ishtiaq; Jerome Gnanaraj; Ché Matthew Harris; Susrutha Kotwal; Waseem Khaliq
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-07-04

2.  Commentary: Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics.

Authors:  Roger Colobran
Journal:  Front Genet       Date:  2020-04-03       Impact factor: 4.599

3.  Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study.

Authors:  Isaac R Melamed; Holly Miranda; Melinda Heffron; Joseph R Harper
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

Review 4.  Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report.

Authors:  Konrad Bork; John T Anderson; Teresa Caballero; Timothy Craig; Douglas T Johnston; H Henry Li; Hilary J Longhurst; Cristine Radojicic; Marc A Riedl
Journal:  Allergy Asthma Clin Immunol       Date:  2021-04-19       Impact factor: 3.406

5.  Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States.

Authors:  Siu Hing Lo; Andrew Lloyd; Shuayb Elkhalifa; Zlatko Sisic; Floortje E van Nooten
Journal:  Pharmacoecon Open       Date:  2021-09-17

6.  Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain.

Authors:  Kyle Staller; Anthony Lembo; Aleena Banerji; Jonathan A Bernstein; Eric D Shah; Marc A Riedl
Journal:  J Clin Gastroenterol       Date:  2022-08-15       Impact factor: 3.174

7.  Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies.

Authors:  Timothy J Craig; Rafael H Zaragoza-Urdaz; H Henry Li; Ming Yu; Hong Ren; Salomé Juethner; John Anderson
Journal:  Allergy Asthma Clin Immunol       Date:  2022-09-24       Impact factor: 3.373

8.  A catalog of the genetic causes of hereditary angioedema in the Canary Islands (Spain).

Authors:  Alejandro Mendoza-Alvarez; Eva Tosco-Herrera; Adrian Muñoz-Barrera; Luis A Rubio-Rodríguez; Aitana Alonso-Gonzalez; Almudena Corrales; Antonio Iñigo-Campos; Lourdes Almeida-Quintana; Elena Martin-Fernandez; Dara Martinez-Beltran; Eva Perez-Rodriguez; Ariel Callero; Jose C Garcia-Robaina; Rafaela González-Montelongo; Itahisa Marcelino-Rodriguez; Jose M Lorenzo-Salazar; Carlos Flores
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

9.  Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study.

Authors:  Douglas T Johnston; Paula J Busse; Marc A Riedl; Marcus Maurer; John Anderson; Christina Nurse; Neil Inhaber; Ming Yu; Aleena Banerji
Journal:  Clin Exp Allergy       Date:  2021-07-05       Impact factor: 5.401

10.  Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change.

Authors:  Kanokvalai Kulthanan; Leena Chularojanamontri; Chuda Rujitharanawong; Puncharas Weerasubpong; Marcus Maurer; Karsten Weller
Journal:  Health Qual Life Outcomes       Date:  2019-10-26       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.